Shengjing Hospital of China Medical University
Shenyang 110136
17 studies enrolling now · 60 studies all time
What they study most
Acute Myocardial Infarction (AMI), Advanced or Metastatic Non-small Cell Lung Cancer, Arthritis, Juvenile, Arthritis, Psoriatic, Atrial Fibrillation, Bladder Cancer, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Cardiovascular Risk, Cerebral Desaturation, Chronic Kidney Disease, Chronic Lymphocytic Leukemia
Studies at this site
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart — Recruiting now
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: — Recruiting now
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) — Recruiting now
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) — Recruiting now
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Recruiting now
- Randomized Study in Children and Adolescents With Migraine: Acute Treatment — Recruiting now
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma — Recruiting now
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation — Recruiting now
- International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery — Recruiting now
- ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — Recruiting now
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma — Recruiting now
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
- A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
- A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer — Running, not enrolling
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
- A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC — Running, not enrolling
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer — Running, not enrolling
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
- A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) — Running, not enrolling
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
- A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations — Running, not enrolling
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer — Running, not enrolling
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension — Running, not enrolling
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) — Running, not enrolling
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Running, not enrolling
- A Study of Guselkumab in Participants With Active Psoriatic Arthritis — Running, not enrolling
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
- A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease — Starting soon
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation — Completed
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Running, not enrolling
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Running, not enrolling
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) — Running, not enrolling
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
- A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling